RS52144B - OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR - Google Patents

OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR

Info

Publication number
RS52144B
RS52144B YU92303A YUP92303A RS52144B RS 52144 B RS52144 B RS 52144B YU 92303 A YU92303 A YU 92303A YU P92303 A YUP92303 A YU P92303A RS 52144 B RS52144 B RS 52144B
Authority
RS
Serbia
Prior art keywords
solution
enantiomer
compound
methylpiperidin
pyrrolo
Prior art date
Application number
YU92303A
Other languages
English (en)
Serbian (sr)
Inventor
Mark Edward Flanagan
Glenn Ernest Wilcox
Christian Koecher
Ton Vries
Michael John Munchhof
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52144(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU92303A publication Critical patent/YU92303A/sh
Publication of RS52144B publication Critical patent/RS52144B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YU92303A 2001-05-31 2002-05-29 OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR RS52144B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06

Publications (2)

Publication Number Publication Date
YU92303A YU92303A (sh) 2006-08-17
RS52144B true RS52144B (en) 2012-08-31

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
YU92303A RS52144B (en) 2001-05-31 2002-05-29 OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR

Country Status (52)

Country Link
US (2) US7301023B2 (instruction)
EP (3) EP1609781B1 (instruction)
JP (1) JP4381137B2 (instruction)
KR (5) KR20060133117A (instruction)
CN (1) CN1729192A (instruction)
AP (1) AP1859A (instruction)
AR (2) AR037321A1 (instruction)
AT (1) ATE519741T1 (instruction)
AU (2) AU2002304401C1 (instruction)
BE (1) BE2017C032I2 (instruction)
BG (1) BG66489B1 (instruction)
BR (1) BR0209246A (instruction)
CA (1) CA2448281C (instruction)
CL (1) CL2008000762A1 (instruction)
CR (1) CR10177A (instruction)
CU (1) CU23337B7 (instruction)
CY (2) CY1113322T1 (instruction)
CZ (1) CZ304366B6 (instruction)
DK (1) DK1666481T3 (instruction)
EA (2) EA012666B1 (instruction)
EC (1) ECSP034865A (instruction)
EE (1) EE05332B1 (instruction)
ES (2) ES2369226T3 (instruction)
FR (1) FR17C1031I2 (instruction)
GE (1) GEP20063784B (instruction)
GT (2) GT200200100A (instruction)
HR (1) HRP20030943B1 (instruction)
HU (2) HU230876B1 (instruction)
IL (1) IL158588A0 (instruction)
IS (1) IS3023B (instruction)
LT (1) LTC1666481I2 (instruction)
LU (1) LUC00031I2 (instruction)
MA (1) MA27029A1 (instruction)
MX (1) MXPA03011062A (instruction)
MY (1) MY129649A (instruction)
NL (1) NL300887I2 (instruction)
NO (3) NO328578B1 (instruction)
NZ (2) NZ540332A (instruction)
OA (1) OA12612A (instruction)
PA (1) PA8546301A1 (instruction)
PE (1) PE20030561A1 (instruction)
PL (2) PL228155B1 (instruction)
PT (1) PT1666481E (instruction)
RS (1) RS52144B (instruction)
SI (1) SI1666481T1 (instruction)
SK (2) SK288199B6 (instruction)
TN (1) TNSN03128A1 (instruction)
TW (2) TWI310384B (instruction)
UA (1) UA80093C2 (instruction)
UY (1) UY27317A1 (instruction)
WO (1) WO2002096909A1 (instruction)
ZA (1) ZA200307982B (instruction)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
HU229671B1 (en) 1999-12-10 2014-04-28 Pfizer Prod Inc Pyrrolo[2,3-d]pirimidine compounds
KR100516419B1 (ko) * 2000-06-26 2005-09-23 화이자 프로덕츠 인크. 면역억제제로서 피롤로[2,3-ｄ]피리미딘 화합물
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
DE60322544D1 (de) * 2002-08-27 2008-09-11 Merck Patent Gmbh Glycinamid-derivate als raf-kinase-hemmer
CN1717236A (zh) 2002-11-26 2006-01-04 辉瑞产品公司 治疗移植排斥的方法
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
WO2005105146A1 (en) * 2004-05-03 2005-11-10 Novartis Ag Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
CA2572314A1 (en) 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
WO2006017443A2 (en) 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
MX2007006204A (es) * 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
CA2615291A1 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CA2614907C (en) * 2005-07-29 2012-02-28 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
PT2455382T (pt) 2005-12-13 2017-01-31 Incyte Holdings Corp Pirrolo[2,3-b]piridinas e pirrolo[2,3-b]pirimidinas substituídas por heteroarilo como inibidores de janus quinases
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2903444T3 (es) 2007-06-13 2022-04-01 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
US8541426B2 (en) * 2007-07-11 2013-09-24 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
CN102007124B (zh) 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
SI2288610T1 (sl) 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
CN102066338A (zh) 2008-04-22 2011-05-18 波托拉医药品公司 蛋白激酶抑制剂
MX2011001259A (es) * 2008-08-01 2011-03-15 Biocryst Pharm Inc Derivados de piperidina como inhibidores jak3.
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
US8592415B2 (en) * 2009-02-11 2013-11-26 Reaction Biology Corp. Selective kinase inhibitors
CA2759026C (en) 2009-04-20 2019-01-15 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
MX2012002641A (es) * 2009-09-10 2012-03-14 Hoffmann La Roche Inhibidores de cinasa janus (jak).
CN105541847B (zh) 2009-10-09 2019-08-16 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
JP5629324B2 (ja) 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
CA2782720A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
US8461328B2 (en) * 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011097087A1 (en) 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
TWI592413B (zh) 2010-03-10 2017-07-21 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
UA111588C2 (uk) 2010-05-21 2016-05-25 Інсайт Холдінгс Корпорейшн Композиція інгібітора jak для місцевого застосування
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
EP2691395B1 (en) 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
CN103459394B (zh) * 2011-04-08 2016-04-27 辉瑞大药厂 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
CN104185420B (zh) * 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3170827A1 (en) 2011-12-15 2017-05-24 ratiopharm GmbH Tofacitinib mono-oxalate salt
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
ES2880814T3 (es) 2012-11-15 2021-11-25 Incyte Holdings Corp Formas de dosificación de liberación sostenida de ruxolitinib
WO2014083150A1 (en) * 2012-11-30 2014-06-05 Lek Pharmaceuticals D.D. Preparation of 3-amino-piperidine compounds via nitro-tetrahydropyridine precursors
WO2014097150A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of tofacitinib and intermediates thereof
WO2014102826A1 (en) 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
AP2015008664A0 (en) 2013-02-22 2015-08-31 Pfizer Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK)
CR20190518A (es) 2013-03-06 2020-01-10 Incyte Corp PROCESOS E INTERMEDIOS PARA HACER UN INHIBIDOR DE JAK (Divisional 2015-0471)
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
KR20160045081A (ko) 2013-08-07 2016-04-26 인사이트 코포레이션 Jak1 억제제용 지속 방출 복용 형태
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
BR112015025543B1 (pt) * 2013-12-09 2020-11-03 Unichem Laboratories Limited processo para a preparação de (3r,4r)-(1-benzil-4- metilpiperidina-3-il)-metilamina e compostos intermediários
US9260438B2 (en) 2014-02-06 2016-02-16 Apotex Inc. Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
MX380276B (es) * 2015-01-20 2025-03-12 Wuxy Fortune Pharmaceutical Co Ltd Inhibidor jak.
KR101791119B1 (ko) * 2015-02-17 2017-11-20 (주)아모레퍼시픽 N-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en) 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
CN107531695B (zh) 2015-04-29 2020-03-27 无锡福祈制药有限公司 Jak抑制剂
JP6761815B2 (ja) 2015-05-01 2020-09-30 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
US10174056B2 (en) 2015-05-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2017017542A1 (en) * 2015-07-27 2017-02-02 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
AU2017287762C1 (en) 2016-06-30 2020-04-23 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
CN111527091B (zh) 2017-12-28 2023-03-28 株式会社大熊制药 作为激酶抑制剂的氧基-氟哌啶衍生物
AU2019213665B2 (en) 2018-01-30 2024-06-13 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
AU2019213835B2 (en) * 2018-01-31 2024-12-19 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
WO2020172714A1 (en) 2019-02-27 2020-09-03 Samson Clinical Pty Ltd Treatment of autoimmune disease
EP3938370A4 (en) 2019-03-13 2022-12-21 Intas Pharmaceuticals Ltd. PROCESS FOR THE PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
EP3946606B1 (en) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
US12227478B2 (en) 2019-04-05 2025-02-18 Yuhan Corporation Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
WO2021094953A1 (en) 2019-11-14 2021-05-20 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
CN114728963B (zh) 2019-11-25 2023-10-31 株式会社大熊制药 新型三唑吡啶衍生物和包括其的药物组合物
IL297050A (en) 2020-04-04 2022-12-01 Pfizer Methods of treating the 2019 corona virus disease
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022194782A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) * 2021-06-23 2025-09-23 合肥华方医药科技有限公司 一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
EP0831829B1 (en) 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
BR9609613A (pt) 1995-07-05 1999-05-25 Du Pont Composto composição fungicida e método de controle de doenças de plantas
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ATE201873T1 (de) 1995-11-14 2001-06-15 Pharmacia & Upjohn Spa Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate
EP0888349B1 (en) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PL331154A1 (en) 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
CA2262421C (en) * 1996-08-23 2007-10-02 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
KR20000057228A (ko) 1996-11-27 2000-09-15 디. 제이. 우드, 스피겔 알렌 제이 축합된 비사이클릭 피리미딘 유도체
DE69839338T2 (de) 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
EP0972197A1 (en) * 1997-03-24 2000-01-19 PHARMACIA & UPJOHN COMPANY Method for identifying inhibitors of jak2/cytokine receptor binding
AU3378799A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted pyrrolo(2,3-b)pyridine and pyrrolo(2,3-d)pyrimidine derivatives: modulators of crf1 receptors
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
HU229671B1 (en) * 1999-12-10 2014-04-28 Pfizer Prod Inc Pyrrolo[2,3-d]pirimidine compounds
KR100516419B1 (ko) 2000-06-26 2005-09-23 화이자 프로덕츠 인크. 면역억제제로서 피롤로[2,3-ｄ]피리미딘 화합물
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
CA2572314A1 (en) * 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity

Also Published As

Publication number Publication date
CZ304366B6 (cs) 2014-04-02
ATE519741T1 (de) 2011-08-15
MA27029A1 (fr) 2004-12-20
WO2002096909A1 (en) 2002-12-05
DK1666481T3 (da) 2012-10-15
MXPA03011062A (es) 2004-03-19
HUP0400152A2 (en) 2007-07-30
PA8546301A1 (es) 2003-05-14
US7432370B2 (en) 2008-10-07
SI1666481T1 (sl) 2012-11-30
KR20060133117A (ko) 2006-12-22
PL367945A1 (en) 2005-03-07
OA12612A (en) 2006-06-09
SK288192B6 (sk) 2014-06-03
EA200301193A1 (ru) 2004-04-29
AU2002304401B2 (en) 2008-04-17
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
MY129649A (en) 2007-04-30
EP1392694A1 (en) 2004-03-03
KR100869409B1 (ko) 2008-11-21
LUC00031I2 (instruction) 2017-10-11
CY1113322T1 (el) 2016-06-22
ECSP034865A (es) 2004-01-28
US7301023B2 (en) 2007-11-27
NO20035201L (no) 2003-11-24
IL158588A0 (en) 2004-05-12
BG66489B1 (bg) 2015-05-29
EP1666481A3 (en) 2006-11-29
TWI316061B (en) 2009-10-21
ES2393385T3 (es) 2012-12-20
CR10177A (es) 2008-08-19
IS3023B (is) 2020-08-15
CA2448281A1 (en) 2002-12-05
EA012666B1 (ru) 2009-12-30
HUP0400152A3 (en) 2012-12-28
TW200413370A (en) 2004-08-01
US20040229923A1 (en) 2004-11-18
KR20080002931A (ko) 2008-01-04
NO20093135L (no) 2003-11-24
EA007251B1 (ru) 2006-08-25
KR100926875B1 (ko) 2009-11-16
HRP20030943B1 (hr) 2011-11-30
LUC00031I1 (instruction) 2017-08-10
CZ20033260A3 (en) 2004-03-17
CY2017028I2 (el) 2018-02-14
PL228155B1 (pl) 2018-02-28
KR20080083028A (ko) 2008-09-12
JP4381137B2 (ja) 2009-12-09
NL300887I2 (nl) 2017-08-31
NO2017047I1 (no) 2017-09-08
EP1666481B9 (en) 2013-05-01
LTC1666481I2 (lt) 2018-06-25
EA200600575A1 (ru) 2006-08-25
UA80093C2 (uk) 2007-08-27
SK288199B6 (sk) 2014-06-03
EP1666481A2 (en) 2006-06-07
BR0209246A (pt) 2004-06-15
GT200200100A (es) 2003-02-11
KR100868814B1 (ko) 2008-11-14
TWI310384B (en) 2009-06-01
KR20040003037A (ko) 2004-01-07
AU2002304401C1 (en) 2009-03-05
CU23337B7 (es) 2009-01-20
EP1609781A1 (en) 2005-12-28
ES2369226T3 (es) 2011-11-28
EE05332B1 (et) 2010-08-16
EP1609781B1 (en) 2011-08-10
BG108389A (bg) 2005-01-31
EP1666481B1 (en) 2012-09-19
US20030073719A1 (en) 2003-04-17
PE20030561A1 (es) 2003-06-23
NZ540332A (en) 2007-05-31
GEP20063784B (en) 2006-04-10
FR17C1031I2 (fr) 2018-11-02
HRP20030943A2 (en) 2005-08-31
PT1666481E (pt) 2012-12-03
EE200300594A (et) 2004-04-15
UY27317A1 (es) 2003-02-28
CL2008000762A1 (es) 2008-07-04
CN1729192A (zh) 2006-02-01
IS6993A (is) 2003-10-13
BE2017C032I2 (instruction) 2021-07-19
AR037321A1 (es) 2004-11-03
AU2008203170A1 (en) 2008-08-07
AU2008203170B2 (en) 2009-06-18
AP1859A (en) 2008-07-02
ZA200307982B (en) 2004-10-14
KR20060014459A (ko) 2006-02-15
HU230876B1 (hu) 2018-11-29
HUS1900008I1 (hu) 2020-02-28
LTPA2017025I1 (lt) 2017-09-11
FR17C1031I1 (fr) 2017-10-13
NZ530380A (en) 2005-08-26
SK14652003A3 (sk) 2004-05-04
NO328578B1 (no) 2010-03-22
TNSN03128A1 (fr) 2005-12-23
YU92303A (sh) 2006-08-17
JP2004534047A (ja) 2004-11-11
NO20035201D0 (no) 2003-11-24
CY2017028I1 (el) 2018-02-14
PL409305A1 (pl) 2014-12-22
CA2448281C (en) 2009-05-05
GT200200100AA (es) 2007-07-06

Similar Documents

Publication Publication Date Title
RS52144B (en) OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
RS50454B (sr) Derivati 2-okso-1-pirolidina, postupak njihovog dobijanja i njihove upotrebe
EA199800882A1 (ru) Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)
CO5271675A1 (es) Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen
MEP24208A (en) Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
YU46787B (sh) Derivati heteroaril 3-okso-propan-nitrila i postupak za njihovo dobijanje
DK0674621T3 (da) Enantiomerer af carbazolderivater som 5-HT1-lignende agonister
BR0212716A (pt) Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica
RU94046047A (ru) Производные аминоуксусной кислоты в виде рацемата или d- и l-энантиомеров и их фармацевтически приемлемые соли, способ получения d- и l-энантиомеров производных аминоуксусной кислоты или их фармацевтически приемлемых солей и промежуточные d- и l-энантиомеры аминоуксусной кислоты в виде цинхонидиновой соли
BR9510429A (pt) Composto composição farmacêutica processo para produzir o composto e uso do composto
ATE42292T1 (de) Imidazo(1,2-c)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
MXPA04002838A (es) Derivados de alquilaminopiridazinona sustituidos, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES8500742A1 (es) Procedimiento para la preparacion de derivados de acido fenilacetico
DK159650C (da) 1,1-diphenylpropan-1-ol-derivater, fremgangsmaade til fremstilling heraf, farmaceutiske praeparater indeholdende disse, samt fremgangsmaade til fremstilling af disse farmaceutiske praeparater
EA200100344A3 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции
HRP20090054T3 (hr) Derivati piperazina alkilnih oksindola
YU60790A (sh) Postupak za dobijanje 5-fenilpirimidin jedinjenja i njihovih soli
RU94042399A (ru) Получения клавулановой кислоты из соли клавулановой кислоты и амина, соли клавулановой кислоты и амина
YU46663B (sh) Postupak za dobijanje kristalnog n-(s-3-alkil- heptanoil)-d-gama-glutamil-glicil-d-alanina
DK1155138T3 (da) Fremgangsmåde til fremstilling af optisk aktive 3,3,3-trifluormethyl-2-alkylpropionsyrederivater
ATE525363T1 (de) Verfahren zur herstellung von dehydro- diketopyperazinen in flüssiger phase oder per festphasensynthese